Introduction：Basic information about CAS 185106-16-5|Acotiamide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Acotiamide |
|---|
| CAS Number | 185106-16-5 | Molecular Weight | 450.552 |
|---|
| Density | 1.2±0.1 g/cm3 | Boiling Point | / |
|---|
| Molecular Formula | C21H30N4O5S | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | N-[2-[di(propan-2-yl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide |
|---|
| Synonym | More Synonyms |
|---|
Acotiamide BiologicalActivity
| Description | Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with IC50 of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory[1][2][3]. |
|---|
| Related Catalog | Research Areas >>Inflammation/ImmunologyResearch Areas >>Metabolic DiseaseSignaling Pathways >>Neuronal Signaling >>AChE |
|---|
| Target | IC50: 1.79 μM (AChE) |
|---|
| In Vitro | Acotiamide (10, 30, 100 μM; 1 hour) reduces expression levels of IκB-α phosphorylation in LPS- and MCP-1-stimulated macrophage cell lines[1]. Cell Viability Assay[1] Cell Line: NR8383, macrophage Concentration: 10, 30, 100 μM Incubation Time: 1 hour Result: Significantly reduced both TNF-α and IL-6 productions in LPS/MCP-1-stimulated NR8383 cells. |
|---|
| In Vivo | Acotiamide (0.3, 1, 3 mg/kg; i.v./3, 10, 30 mg/kg; p.o.) increases the postprandial gastric motility index in a dose-dependent manner[2]. Acotiamide (0.83 mg/kg; i.v.; once) inhibits AChE in rat stomach with IC50 of 1.79 μM[3]. Animal Model: Male mongrel dogs (9-11 kg), Male beagle dogs (9.6-12.9 kg)[2] Dosage: 0.3, 1, 3, 10, 30 mg/kg Administration: Intravenous injection; once Result: Increased the postprandial gastric motility. Animal Model: Male Sprague-Dawley rats (aged 6-7 weeks)[3] Dosage: 0.83 mg/kg Administration: Intravenous injection; once. Result: Effectively improved functional dyspepsia by inhibiting AChE in rat stomach. |
|---|
| References | [1]. Kazuyoshi Y oshii, et al. Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling for the Inhibition of Acetylcholinesterase by Acotiamide, A Novel Gastroprokinetic Agent for the Treatment of Functional Dyspepsia, in Rat Stomach. Pharmaceutical Research, 33(2), 292–300. [2]. Hiroshi Yamawaki, et al. Acotiamide attenuates central urocortin 2-induced intestinal inflammatory responses, and urocortin 2 treatment reduces TNF-α productions in LPS-stimulated macrophage cell lines. Neurogastroenterol Motil. 2020 Aug;32(8):e13813. [3]. Matsunaga Y, Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011 Mar;336(3):791-800. |
|---|
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|
| Molecular Formula | C21H30N4O5S |
|---|
| Molecular Weight | 450.552 |
|---|
| Exact Mass | 450.193695 |
|---|
| PSA | 148.24000 |
|---|
| LogP | 3.56 |
|---|
| Index of Refraction | 1.592 |
|---|
| InChIKey | TWHZNAUBXFZMCA-UHFFFAOYSA-N |
|---|
| SMILES | COc1cc(O)c(C(=O)Nc2nc(C(=O)NCCN(C(C)C)C(C)C)cs2)cc1OC |
|---|
| Storage condition | -20℃ |
|---|
Synonyms
| Acotiamide |
| MZ-338 |
| N-[2-(Diisopropylamino)ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide |
| UNII-D42OWK5383 |
| 4-Thiazolecarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]- |
